北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
作者: Jin, Xuan2; Ding, Huirong3; Ding, Ning1; Fu, Zhiying1; Song, Yuqin1; Zhu, Jun1
关键词: Complement ; Polymorphism ; Rituximab ; DLBCL ; C1qA
刊名: JOURNAL OF HEMATOLOGY & ONCOLOGY
发表日期: 2012-08-16
DOI: 10.1186/1756-8722-5-51
卷: 5
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Hematology
研究领域[WOS]: Oncology ; Hematology
关键词[WOS]: CHRONIC LYMPHOCYTIC-LEUKEMIA ; CHEMOTHERAPY PLUS RITUXIMAB ; C1Q BINDING-SITE ; ELDERLY-PATIENTS ; IN-VIVO ; EFFECTOR MECHANISMS ; ANTIBODY ; ACTIVATION ; EXPRESSION ; INHIBITORS
英文摘要:

Background: The precise mechanism of action for rituximab (R) is not fully elucidated. Besides antibody-dependent cellular cytotoxicity (ADCC), complements may also play an important role in the clinical response to rituximab-based therapy in diffuse large B cell lymphoma (DLBCL). The purpose of this study was to explore the relationship between C1qA([276]) polymorphism and the clinical response to standard frontline treatment with R-CHOP in DLBCL patients.

Methods: Genotyping for C1qA([276A/G]) was done in 164 patients with DLBCL. 129 patients treated with R-CHOP as frontline therapy (R >= 4 cycles) were assessable for the efficacy.

Results: Patients with homozygous A were found to have a higher overall response rate than those with heterozygous or homozygous G alleles (97.3% vs. 83.7%, P = 0.068). The complete response rate in patients with homozygous A was statistically higher than that in AG and GG allele carriers (89.2% vs. 51.1%, P = 0.0001). The overall survival of patients with homozygous A was longer than that of the G allele carriers (676 days vs. 497 days, P = 0.023). Multivariate Cox regression analysis showed that C1qA A/A allele was an independent favorable prognostic factor for DLBCL patients treated with R-CHOP as first-line therapy.

Conclusion: These results suggest that C1qA polymorphism may be a biomarker to predict response to R-CHOP as frontline therapy for DLBCL patients.

语种: 英语
所属项目编号: 30973484
项目资助者: National Science Foundation Committee of China
WOS记录号: WOS:000309879700001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/67061
Appears in Collections:北京大学临床肿瘤学院_淋巴肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Hosp 1, Dept Internal Med Oncol, Beijing 100034, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Cent Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China

Recommended Citation:
Jin, Xuan,Ding, Huirong,Ding, Ning,et al. Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY,2012,5.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Jin, Xuan]'s Articles
[Ding, Huirong]'s Articles
[Ding, Ning]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Jin, Xuan]‘s Articles
[Ding, Huirong]‘s Articles
[Ding, Ning]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace